ABCB4 and cholestasis: In the Mdr2-/- cholestatic mouse model inhibition of miR-873-5p for only 4 weeks starting at the time at which an overt inflammation, cholestasis, and severe fibrosis is observed (4 months old mice), resulted in reduced BA-related cell death and cholangiocyte proliferation, with mild blunted inflammation and decreased fibrosis related markers.